` 0RA9 (Abivax SA) vs DAX Index Comparison - Alpha Spread

0RA9
vs
D
DAX Index

Over the past 12 months, 0RA9 has significantly outperformed DAX Index, delivering a return of +1 654% compared to the DAX Index's +14% growth.

Stocks Performance
0RA9 vs DAX Index

Loading
0RA9
DAX Index
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
0RA9 vs DAX Index

Loading
0RA9
DAX Index
Difference
www.alphaspread.com

Performance By Year
0RA9 vs DAX Index

Loading
0RA9
DAX Index
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Abivax SA vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Abivax SA
Glance View

Market Cap
1B EUR
Industry
Biotechnology

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

0RA9 Intrinsic Value
16.56 EUR
Overvaluation 84%
Intrinsic Value
Price €104.7
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett